CAMPBELL, Calif., April 4, 2019 /PRNewswire/ — VivaLNK, a leading provider of connected healthcare solutions, has been selected to participate in Plug & Play’s Silicon Valley Health Batch 8 Program lasting 12 weeks.
Plug and Play, a leading Global Innovation Platform, operates industry specific, stage-agnostic platforms that help startups and growth-stage companies raise funding and pursue business development opportunities in collaboration with corporations. Through the development of a world-class ecosystem, Plug and Play provides entrepreneurs with opportunities to succeed through guidance from local startups, growth-stage companies, investors, mentors, and Fortune 500 corporations.
The Health Batch 8 program is designed to connect innovative healthcare technology and solution companies with corporate partners to disrupt the healthcare industry by challenging clinical practices, improving data analytics, and enhancing the patient journey across the care continuum.
“We’re very proud to be among only 20 companies selected from more than 850 candidates to participate in the Health Batch 8 program,” said Jiang Li, CEO of VivaLNK. “With our unique Medical IoT Sensor platform, we look forward to engaging with customers, partners and investors to accelerate and promote healthcare innovation throughout the world.”
For information about VivaLNK, visit: www.vivalnk.com.
For information about Plug and Play, visit: www.plugandplaytechcenter.com.
About VivaLNK
VivaLNK is a provider of connected healthcare solutions for wellness, patient care, and telemedicine. The company’s portfolio includes wearable medical grade devices and data analytics applications that continuously monitor the health and well-being of individuals. The company’s vision is to improve the quality and accessibility of healthcare worldwide by combining technology, data, and analytics into an integrated solution.
Media Contact:
pr@VivaLNK.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/vivalnk-selected-to-plug-and-plays-silicon-valley-health-batch-8-program-300824536.html
SOURCE VivaLNK
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…